Expression of integrin α vβ 3 in medullary thyroid carcinoma.
Publication date
2024
Authors
de Vries, Lisa
Lodewijk, Lutske
Pijnappel, Emma W
van Diest, Paul J
Schepers, Abbey
Bonenkamp, Han J
van Engen-van Grunsven, Ilse Ach
Kruijff, Schelto
van Hemel, Bettien M
Links, Thera P
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Aim: Tumor markers often remain elevated after intended curative resection of medullary thyroid carcinoma (MTC). The aim of this study was to determine the expression of α vβ 3, a promising theranostics target, in MTC and its metastases. Materials & methods: A vβ 3 expression was analyzed in 104 patients using a tissue microarray and correlated with clinicopathological variables and survival. Results: Cytoplasmic α vβ 3 positivity was seen in 70 patients and was associated with lymph node metastases at time of initial surgery. Membranous positivity was considered positive in 30 patients and was associated with sporadic MTC. Conclusion: A vβ 3 was expressed in the cytoplasm of 67% of MTC patients. Membranous expression, which is presumably most relevant for the theranostic use of α vβ 3, was seen in 29%.
Keywords
medullary thyroid carcinoma, nuclear imaging, nuclear therapy, tissue microarray, α β, Oncology, Cancer Research
Citation
de Vries, L H, Lodewijk, L, Pijnappel, E W, van Diest, P J, Schepers, A, Bonenkamp, H J, van Engen-van Grunsven, I A, Kruijff, S, van Hemel, B M, Links, T P, Nieveen van Dijkum, E J, Eeden, S V, van Leeuwaarde, R S, Valk, G D, Keizer, B D, Borel Rinkes, I H & Vriens, M R 2024, 'Expression of integrin α vβ 3 in medullary thyroid carcinoma.', Future Oncology, vol. 20, no. 27, pp. 2015-2022. https://doi.org/10.1080/14796694.2024.2376511